NeuroStar TMS Therapy
Device
Neuronetics, Inc.
Total Payments
$2.6M
Transactions
2,781
Doctors
1,291
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $10,800 | 1 | 1 |
| 2020 | $52,581 | 15 | 2 |
| 2019 | $31,135 | 10 | 1 |
| 2018 | $640,377 | 55 | 0 |
| 2017 | $1.8M | 2,700 | 1,290 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 248 | 66.3% |
| Royalty or License | $538,680 | 8 | 21.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $90,313 | 69 | 3.5% |
| Consulting Fee | $87,652 | 9 | 3.4% |
| Food and Beverage | $79,371 | 2,405 | 3.1% |
| Gift | $33,654 | 1 | 1.3% |
| Honoraria | $19,200 | 8 | 0.7% |
| Travel and Lodging | $16,300 | 32 | 0.6% |
| Entertainment | $1,500 | 1 | 0.1% |
Payments by Type
Research
$1.7M
248 transactions
General
$866,670
2,533 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents | Neuronetics, Inc. | $1.7M | 3 |
| Utility of Repetitive Transcranial Magnetic Stimulation (TMS) in Promoting Rapid Psychiatric Stabilization in Acutely Suicidal Military Service Members | Neuronetics, Inc. | $3,868 | 0 |
| A Study of Bilateral Prefrontal Transcranial Magnetic Stimulation (TMS) to Treat the Symptoms of Mild TBI (mTBI) and PTSD | Neuronetics, Inc. | $1,841 | 0 |
| Combined Therapy With rTMS and Botulinum Toxin in Primary Cervical Dystonia | Neuronetics, Inc. | $1,660 | 0 |
| Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders | Neuronetics, Inc. | $613.50 | 0 |
Top Doctors Receiving Payments for NeuroStar TMS Therapy
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $2.2M | 250 |
| , MD, JD | Psychiatry | North Wales, PA | $60,000 | 4 |
| , M.D | Psychiatry | Pasadena, CA | $35,463 | 23 |
| , M.D | Obstetrics & Gynecology | Spokane, WA | $33,654 | 1 |
| , MD | Psychiatry | Tampa, FL | $29,491 | 61 |
| , M.D | Psychiatry | Baltimore, MD | $22,952 | 15 |
| , MD | Psychiatry | Cumming, GA | $14,673 | 21 |
| , M.D | Psychiatry | Malvern, PA | $7,901 | 10 |
| , M.D | Neurology | Philadelphia, PA | $7,426 | 2 |
| , DO | Addiction Medicine | Dallas, TX | $6,581 | 15 |
| , MD | Psychiatry | Boston, MA | $6,201 | 2 |
| , MD | Psychiatry | Stanford, CA | $6,153 | 5 |
| , M.D | Psychiatry | Sugar Land, TX | $5,811 | 19 |
| , M.D | Psychiatry | Kissimmee, FL | $3,363 | 13 |
| , MD | Psychiatry | Cincinnati, OH | $3,176 | 8 |
| , M.D | Psychiatry | Little Rock, AR | $3,167 | 12 |
| , MD | Psychiatry | Toledo, OH | $3,110 | 7 |
| , MD | Psychiatry | Glenview, IL | $2,824 | 7 |
| , D.O | Psychiatry | Dallas, TX | $2,806 | 11 |
| , MD | Addiction Medicine | Columbia, MO | $2,613 | 11 |
| , M.D | Psychiatry | Worcester, MA | $1,980 | 4 |
| , D.O | Child & Adolescent Psychiatry | Nesconset, NY | $1,609 | 3 |
| , MD | Clinical Neurophysiology | Washington, DC | $1,435 | 2 |
| , M.D | Psychiatry | Danbury, CT | $1,193 | 15 |
| , M.D | Psychiatry | Garden City, NY | $1,048 | 3 |
Ad
Manufacturing Companies
- Neuronetics, Inc. $2.6M
Product Information
- Type Device
- Total Payments $2.6M
- Total Doctors 1,291
- Transactions 2,781
About NeuroStar TMS Therapy
NeuroStar TMS Therapy is a device associated with $2.6M in payments to 1,291 healthcare providers, recorded across 2,781 transactions in the CMS Open Payments database. The primary manufacturer is Neuronetics, Inc..
Payment data is available from 2017 to 2021. In 2021, $10,800 was paid across 1 transactions to 1 doctors.
The most common payment nature for NeuroStar TMS Therapy is "Unspecified" ($1.7M, 66.3% of total).
NeuroStar TMS Therapy is associated with 5 research studies, including "A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents" ($1.7M).